Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetic Services Laboratory, |
RCV000501883 | SCV000596148 | pathogenic | Tyrosinase-positive oculocutaneous albinism | 2017-02-17 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001857136 | SCV002289331 | pathogenic | not provided | 2024-12-16 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 7 of the OCA2 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in OCA2 are known to be pathogenic (PMID: 19865097, 21541274). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. Disruption of this splice site has been observed in individuals with ocular albinism (PMID: 34838614). ClinVar contains an entry for this variant (Variation ID: 436095). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV002490839 | SCV002796167 | pathogenic | Tyrosinase-positive oculocutaneous albinism; SKIN/HAIR/EYE PIGMENTATION 1, BLUE/NONBLUE EYES | 2024-05-16 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003470630 | SCV004209030 | likely pathogenic | SKIN/HAIR/EYE PIGMENTATION 1, BLUE/NONBLUE EYES | 2023-06-01 | criteria provided, single submitter | clinical testing |